Summit Therapeutics Share Discussion Threads

[tightfist] 27/10/2016 09:13

FYI, Yahoo! also shows 225k

[theunluckyone] 27/10/2016 09:06

waterloo01 - ADVFN figures showed 225K approx but they have now cleared all the figures but will recheck later when they reappear

[waterloo01] 27/10/2016 08:54

145k shares x 5 = 725k

[theunluckyone] 27/10/2016 08:51

waterloo01 - Over 1 million traded surely on NASDAQ yesterday

[waterloo01] 27/10/2016 08:44

Volume on Nasdaq yesterday equivalent to 750,000 shares. Compare that with AIM volume, which is relatively tiny. Ultimately I guess that's what GW found.

[someuwin] 27/10/2016 08:02

Can't buy many online.

[freedosh] 26/10/2016 22:29

Up another 2.55% in after hours trading on NASDAQ
Christmas tomorrow?

[waterloo01] 26/10/2016 21:09

Top biotech gainer on Nasdaq today. Should gain some attention (even if the attention span is somewhat limited).

[abergele] 26/10/2016 20:50

I expect we shall see a rush here tomoz to load up,
over 10% up on nasdac,
yet only 2% here,,poor or what,,
a re-rate please....gla lh's

[football] 26/10/2016 20:32

Stock of the Day: It Seems Summit Therapeutics PLC (ADR) Will Go Up. Have Another Big Increase

[waterloo01] 26/10/2016 19:50

$10 should be the bottom of the channel with $19 as the current top. Nasdaq will find it's level and I would think between $12.50 and $15 is were it will settle, news aside.

I have a feeling the sponsor of the event today is closely involved in our RDZ talks. All IMO.

[hugus maximus] 26/10/2016 19:35

Waterloo $12.50 would be approx £2.05p at today's dollar / pound exchange ... so not such a ridiculous thought.

[hugus maximus] 26/10/2016 19:30

SMMT and SRPT today

Newton's 3rd Law in action -

"When one body exerts a force on a second body, the second body simultaneously exerts a force equal in magnitude and opposite in direction on the first body."

... maybe this IS Sarepta investors finally selling out to buy into Summit ;-/

[waterloo01] 26/10/2016 18:35

Over 600k shares equivalent traded so far. Hopefully this time it will hold above $12.50.

[hugus maximus] 26/10/2016 17:26

Hi Chris .. there does seem to be a sudden burst of enthusiasm ;-)

Edit - we're talking a 45˚ rise on the NASDAQ so far today. To quote Van Morrison:
"Wouldn't it be great if it was like this all the time".

[chrisatrdg] 26/10/2016 17:20

Hi Hugus Maximus as previously posted I think this could be a well deserved re-rate considering the increase in Summits share price ratings.

Edit: Further Summit cover

[hugus maximus] 26/10/2016 16:54

Extraordinary .. summut's up ... but why? What do folk know aside from analysts continuing to upgrade prospects? (Not complaining!)

[freemoney1] 26/10/2016 16:42

Sasannach, I think this is the one you're looking for:
hxxps://www.thecerbatgem.com/2016/10/26/summit-therapeutics-plc-smmt-receives-23-80-consensus-pt-from-brokerages.html

But that average is dragged down by some not rerating after the SRPT deal. The average is more around $30 I think if you just include the up to date brokers.

Long way to go for fair value compared to our peers though, but maybe US investors are realising that now.... looking good :-)

[waterloo01] 26/10/2016 16:42

This was on today . We aren't directly involved (although I think we have someone attending) but it might have been written for RDZ. I did point it out a few weeks ago.



Program Objectives:

Upon completion of this activity, participants will be able to:

Investigate the clinical potential of narrow-spectrum antibacterial agents
Identify properties and the clinical potential of new antibacterial agents in early and late stage development
Order rapid diagnostic tests for bacterial detection / identification and will be updated on newly developed technologies to optimize therapy
Recognize the importance of the human microbiome and impact of broad and narrow spectrum antibacterial agents upon metabolic processes

More about the sponsors:



Debiopharm International SA searches, evaluates and in-licenses promising drug candidates for development. Towards the end of the development process, the products are licensed out to pharmaceutical companies for world-wide marketing and sales.

[chrisatrdg] 26/10/2016 16:36

Now up 14.35% on NASDAQ is this the re-rating Summit deserves I also agree with someuwin cheaper to Buy Summit than SRPT (down 2.6% on NASDAQ).

[sasannach] 26/10/2016 16:35

I can see an article on my ipad on the Cerbat Gem
"Summit Therapeutics receives $23.80 Consensus PT from Brokers"

But the website through my PC isn't showing the article!!
hxxp://www.thecerbatgem.com/category/health

===================
Summit Therapeutics PLC logoSummit Therapeutics PLC (NASDAQ:SMMT) has been given a $28.00 price target by stock analysts at Canaccord Genuity in a note issued to investors on Monday. The brokerage presently has a a “buy” rating on the stock. Canaccord Genuity’s price target suggests a potential upside of 154.31% from the company’s previous close.

Several other equities analysts also recently commented on SMMT. Zacks Investment Research downgraded shares of Summit Therapeutics PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. HC Wainwright started coverage on shares of Summit Therapeutics PLC in a research note on Friday, September 16th. They issued a “buy” rating and a $26.00 price objective for the company. Needham & Company LLC increased their price objective on shares of Summit Therapeutics PLC from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, October 4th. Finally, Oppenheimer Holdings Inc. reissued an “outperform221; rating and issued a $28.00 price objective on shares of Summit Therapeutics PLC in a research note on Wednesday, October 5th. Six investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $23.80.

Analyst Recommendations for Summit Therapeutics PLC (NASDAQ:SMMT)

Shares of Summit Therapeutics PLC (NASDAQ:SMMT) opened at 11.01 on Monday. The stock has a 50 day moving average price of $0.00 and a 200 day moving average price of $0.00. Summit Therapeutics PLC has a 12 month low of $4.26 and a 12 month high of $19.75.

A hedge fund recently bought a new stake in Summit Therapeutics PLC stock. Granite Point Capital Management L.P. purchased a new stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) during the second quarter, according to its most recent filing with the SEC. The institutional investor purchased 112,676 shares of the company’s stock, valued at approximately $891,000. Granite Point Capital Management L.P. owned approximately 0.92% of Summit Therapeutics PLC as of its most recent SEC filing. Hedge funds and other institutional investors own 23.43% of the company’s stock.

About Summit Therapeutics PLC

Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

[someuwin] 26/10/2016 16:26

10%+ in the US.

[freedosh] 26/10/2016 15:43

Summthings up IMO

[someuwin] 26/10/2016 15:32

Has the recent deal news focussed peoples attention?

Are they perhaps selling out of SRPT to buy into the much cheaper SMMT?